DIM
HOWL icon

Delta Investment Management’s Werewolf Therapeutics HOWL Stock Holding History

Delta Investment Management’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4K Hold
14,925
– – ﹤0.01% 273
2025
Q4 		$9.46K Buy
+14,925
New +$18.1K ﹤0.01% 280

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Delta Investment Management's HOWL Position: Q1 2026 in Review

Delta Investment Management held its Werewolf Therapeutics (HOWL) position steady in Q1 2026 at 14,925 shares worth $12.4K. The position accounts for ﹤0.01% of the portfolio, ranked #273.

Delta Investment Management first reported a position in HOWL in Q4 2025 and has held it in 2 quarters since. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Delta Investment Management held 14,925 shares of Werewolf Therapeutics worth $12.4K as of Q1 2026.
  • Delta Investment Management left its Werewolf Therapeutics share count unchanged in Q1 2026.
  • Werewolf Therapeutics made up ﹤0.01% of Delta Investment Management's portfolio in Q1 2026, its #273 holding.
  • Delta Investment Management first reported a position in Werewolf Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Delta Investment Management's 13F filing for Q1 2026, filed 13 May 2026.